The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

Medicine & Life Sciences

• dactolisib 95%
• small inducible cytokine subfamily E, member 1 76%
• TOR Serine-Threonine Kinases 64%
• gemcitabine 58%
• Phosphatidylinositol 3-Kinase 58%
• Pancreatic Neoplasms 54%
• Drug Therapy 33%
• Adenocarcinoma 28%
• Poly (ADP-Ribose) Polymerase-1 7%
• Group Psychotherapy 5%
• Heterografts 4%
• Caspase 3 4%
• In Vitro Techniques 4%
• Psychological Inhibition 4%
• Fibroblasts 3%
• Proteins 3%
• Western Blotting 3%
• Cell Proliferation 3%
• Apoptosis 3%
• Cell Line 3%
• Animals 2%
• Therapeutics 2%

Chemical Compounds

• Mammalian Target of Rapamycin Inhibitor 100%
• Gemcitabine 86%
• Antiangiogenic 79%
• Polypeptide 42%
• Poly(ADPribose) 8%
• Western Blotting 8%
• Antitumor 5%
• Protein 5%
• Additive 4%